Drug intelligence / Profile preview

JS211

Development stage: Preclinical
Lead developer: Li Ning
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JS211 is a bispecific oncology drug candidate being developed by Shanghai Junshi Biosciences. It is designed to simultaneously target the Programmed Death-Ligand 1 (PD-L1) or Programmed Cell Death Protein 1 (PD-1) pathway along with an undisclosed second target. By combining checkpoint inhibition with a second mechanism of action, JS211 aims to enhance the anti-tumor immune response and potentially overcome resistance seen with monotherapy. As of 2021-2022, the drug was in preclinical development, and it remains part of the company's extensive oncology pipeline for the treatment of various unspecified tumors.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on JS211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS211.

Explore the full profile